Drug approved to treat high blood pressure

April 13, 2012

(HealthDay) -- The high blood pressure drug Toprol XL has been combined with a low-dose diuretic to form Dutoprol (metoprolol succinate extended release/hyrdrochlorothiazide), which has been approved by the U.S. Food and Drug Administration to treat high blood pressure.

Toprol XL has been approved in the United States for 20 years as a treatment for hypertension, British drugmaker AstraZeneca said in a news release.

The drug maker said it will charge $18.33 per month when a 90-day supply of the combination drug is ordered with a valid prescription, whether or not the patient has insurance. Retail drug stores also will stock the combination medication.

AstraZeneca said the drug may not be recommended for people with a significantly slow heart rate, uncontrolled heart failure, or allergies to the drug's ingredients.

Explore further: Novartis drug investigated after 11 deaths

More information: Medline Plus has more information about Dutoprol's active ingredient.

Related Stories

Two pancreatic-enzyme products approved

March 2, 2012

(HealthDay) -- Two drugs that supplement the digestion-aiding actions of pancreatic enzymes have been approved by the U.S. Food and Drug Administration, the agency said Thursday in a news release.

Recommended for you

Re-framing the placebo effect and informed consent

October 29, 2015

(Medical Xpress)—Imagine that your doctor knows from evidence-based studies that if he tells you about certain, small side-effects to a particular drug, you are significantly more likely to experience that side effect than ...

Can exercise be replaced with a pill?

October 2, 2015

Everyone knows that exercise improves health, and ongoing research continues to uncover increasingly detailed information on its benefits for metabolism, circulation, and improved functioning of organs such as the heart, ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.